Related Experiment Video
Updated: May 29, 2025
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Days of antibiotic spectrum coverage (DASC) as predictors of recurrent Clostridioides difficile infection: A
Nobuaki Mori1, Yuichi Shibata2, Jun Hirai1
1Department of Clinical Infectious Diseases, Aichi Medical University, 1-1 Yazakokarimata, Nagakute-shi, Aichi, 480-1195, Japan; Department of Infection Prevention and Control, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute-shi, Aichi, 480-1195, Japan.
Background:
Broad-spectrum antibiotic use increases the risk of Clostridioides difficile infection (CDI), with recurrence rates varying by antibiotic type, spectrum, and treatment duration. We assessed CDI recurrence risk using the days of antibiotic spectrum coverage (DASC) score, considering antibiotic spectrum and use duration.
Methods:
We retrospectively analyzed patients with hospital-acquired CDI. A logistic regression analysis was used to evaluate CDI recurrence, incorporating three variables: DASC score prior to CDI diagnosis, type of anti-CDI drugs, or DASC score after CDI diagnosis.
Results:
Overall, 246 patients were included, with 31 (12.6 %) cases of recurrence. Median DASC scores within 30 days prior to CDI diagnosis were higher in the recurrent group than in the non-recurrent group (128 [interquartile range: 106-217] vs. 80 [interquartile range: 39-142], p < 0.01). Using the lowest quartile of DASC scores as the reference, the analysis indicated higher relative risks of CDI recurrence in the upper quartiles. However, daily DASC scores post-CDI diagnosis did not correlate with recurrence. Compared to metronidazole, fidaxomicin lowered the risk of CDI recurrence (relative risk 0.2, 95 % confidence interval: 0.1-0.8, p = 0.03).
Conclusions:
The DASC score within 30 days prior to CDI diagnosis appears to be a predictive risk factor for CDI recurrence.
More Related Videos
09:12A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
06:51Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
